Follow us...

 

Search News Archives

 

Special Offers and Promotions

 

 

News Channels

 

Laboratory Products

 

 

View Channel

News

 

 

View Channel

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events
Panthera Biopartners

Panthera Biopartners

Panthera Biopartners

Products

Contact Panthera Biopartners


If you have not logged into the website then please enter your details below.

All articles from Panthera Biopartners

  Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study

Panthera has started vaccinating volunteers in Valneva’s double-blind, phase three, COVID prevention trial. The trial will compare Valneva’s inactivated vaccine, VLA2001, with AstraZeneca’s conditionally approved vaccine Vaxzeria. Unlike earlier COVID-19 vaccine trials, which involved a placebo dose, everyone involved in this study will receive two active vaccine doses....

 

  Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19

Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of COVID-19. The double-blind, placebo-controlled trial will include adult volunteers who have no history of COVID-19 and have an increased risk of infection...

 

  Independent Site Management Organisation Panthera prepares for COVID-19

Independent Site Management Organisation Panthera is working with sponsors who need to press ahead with trials which can be done safely. “The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to assess each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants” commented Stuart Young CEO...

 

 

Media Partners